Tyler Quigley, PhD
1.1K posts
Introducing Qualitate. AI built for primary intelligence. Qualitate conducts thousands of expert discussions each month, delivering structured intelligence for the world’s leading investment firms and enterprises. Here's how:
Meet the new Stitch, your vibe design partner. Here are 5 major upgrades to help you create, iterate and collaborate: 🎨 AI-Native Canvas 🧠 Smarter Design Agent 🎙️ Voice ⚡️ Instant Prototypes 📐 Design Systems and DESIGN.md Rolling out now. Details and product walkthrough video in 🧵
Google Stitch is interesting but let’s be honest about what it is. Spell check didn’t make anyone a better writer. It just made bad writing less frequent. That’s what AI design tools do. They clean up the mess. They don’t create the vision. You can prompt claude code, gemini, or any of them and they will all give you something competent. Not bad. Just not interesting. When everyone has access to “pretty good,” pretty good stops working. It becomes noise. The baseline shifts and very rapidly the only stuff that cuts through the noise is the stuff that has a point of view. That takes an eye and imagination and I promise you no prompt box is ever gonna give you that. In summary, good designers are definitely not cooked.
Make no mistake @benryanwriter, I have learned from my work on Pharma, this study will not slow down the push for psychedelics. It’s accelerating, backed by a sophisticated funding ecosystem. The bottom line is that the “psychedelic treatment movement” is no longer just a scientific or cultural story—it’s a financial one. With projections pushing the market toward ~$11 billion by 2027, the incentives are enormous. The money pipeline: 1. Philanthropic capital, including the Steven & Alexandra Cohen Foundation, Bob & Renee Parsons and Tim Ferriss and a network of startup founders and investors. 2. Venture capital + biotech Companies are not just studying psychedelics—they’re engineering, patenting, and monetizing them: – Compass Pathways developing synthetic psilocybin (COMP360); Aset Life Sciences building a portfolio of psychedelic therapeutics; and MindMed and GH Research pursuing proprietary LSD and DMT-based compounds This is IP strategy, clinical pipelines, and FDA pathways—classic pharma playbooks. 3. Government funding – VA funding psychedelic research again for the first time in decades – Texas committing $50 million to ibogaine research for PTSD and addiction – Additional state-level initiatives expanding rapidly 4. Lobbying + regulatory strategy Advocacy groups and industry players are actively shaping policy: – MAPS and its for-profit arm pushing MDMA through FDA approval – Policy networks and corporate lobbyists working on “trigger laws” to fast-track access once approved This is coordinated, strategic, and well-funded. Once a pipeline like this is built, it rarely reverses direction simply because the clinical studies prove there is poor treatment efficacy
Ten years ago, Trump was just coming on the scene and I was ALL IN on his idea of “MAGA”. I was a VERY consistent, faithful, and loyal supporter for close to a decade following… Voted for Trump three times, and made sure to use my platform to advocate my support and petition votes for him, at every turn. Today, it’s like I was supporting a man who never really existed in the first place… It was all just a MASSIVE ILLUSION & CON.
Minds require altered states of consciousness for optimal functioning and creative output. In this week's episode of Parallel Mind, I will discuss the role of psychopharmacology within the context of novel communities and parallel ecosystems. twitter.com/i/spaces/1kvKp…
hello i would like to report a murder
